CZ297440B6 - Lék pro prevenci nefrotoxicity nebo renální dysfunkce a farmaceutický prostredek - Google Patents

Lék pro prevenci nefrotoxicity nebo renální dysfunkce a farmaceutický prostredek Download PDF

Info

Publication number: CZ297440B6
Authority: CZ; Czechia
Prior art keywords: pps; cyclosporin; pharmaceutically acceptable; composition; pharmaceutical composition
Prior art date: 1997-10-09

Application number

CZ20001274A

Other languages

Czech (cs)

English (en)

Other versions

CZ20001274A3 (cs

Inventor

E. Striker@Gary

Striker@Lilliane

H. Kortright@Kenneth

Original Assignee

Baker Norton Pharmaceuticals, Inc.

The United States Of America, Represented By The Secretary Department Of Health & Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-09

Filing date

1998-10-09

Publication date

2006-12-13

1998-10-09 Application filed by Baker Norton Pharmaceuticals, Inc., The United States Of America, Represented By The Secretary Department Of Health & Human Services filed Critical Baker Norton Pharmaceuticals, Inc.

2001-12-12 Publication of CZ20001274A3 publication Critical patent/CZ20001274A3/cs

2006-12-13 Publication of CZ297440B6 publication Critical patent/CZ297440B6/cs

Links

231100000417 nephrotoxicity Toxicity 0.000 title claims abstract description 24
206010029155 Nephropathy toxic Diseases 0.000 title claims abstract description 23
230000007694 nephrotoxicity Effects 0.000 title claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
230000008085 renal dysfunction Effects 0.000 title claims abstract description 10
239000003814 drug Substances 0.000 title claims abstract description 7
229940043138 pentosan polysulfate Drugs 0.000 claims abstract description 90
229930182912 cyclosporin Natural products 0.000 claims abstract description 58
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 47
108010036949 Cyclosporine Proteins 0.000 claims abstract description 47
229960001265 ciclosporin Drugs 0.000 claims abstract description 47
150000003839 salts Chemical class 0.000 claims abstract description 34
210000003734 kidney Anatomy 0.000 claims abstract description 33
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 32
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract description 28
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract description 28
229960001967 tacrolimus Drugs 0.000 claims abstract description 28
239000000203 mixture Substances 0.000 claims abstract description 22
230000001506 immunosuppresive effect Effects 0.000 claims abstract description 12
206010062016 Immunosuppression Diseases 0.000 claims abstract description 9
230000003176 fibrotic effect Effects 0.000 claims abstract description 6
208000032544 Cicatrix Diseases 0.000 claims abstract description 5
231100000241 scar Toxicity 0.000 claims abstract description 5
230000037387 scars Effects 0.000 claims abstract description 5
230000001939 inductive effect Effects 0.000 claims abstract description 4
239000002552 dosage form Substances 0.000 claims description 23
108010036941 Cyclosporins Proteins 0.000 claims description 16
230000003902 lesion Effects 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 10
206010016654 Fibrosis Diseases 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
230000004761 fibrosis Effects 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 6
238000011260 co-administration Methods 0.000 claims description 6
239000003826 tablet Substances 0.000 claims description 6
-1 cachets Substances 0.000 claims description 5
239000000945 filler Substances 0.000 claims description 5
159000000000 sodium salts Chemical class 0.000 claims description 5
239000011230 binding agent Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
239000003018 immunosuppressive agent Substances 0.000 claims description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
229940125721 immunosuppressive agent Drugs 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
239000007937 lozenge Substances 0.000 claims description 3
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
239000007950 delayed release tablet Substances 0.000 claims description 2
238000011161 development Methods 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
235000019359 magnesium stearate Nutrition 0.000 claims description 2
229940057948 magnesium stearate Drugs 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims 3
239000007939 sustained release tablet Substances 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 11
230000006378 damage Effects 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 abstract description 3
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 91
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 24
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 22
AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 19
238000000034 method Methods 0.000 description 16
241000700159 Rattus Species 0.000 description 14
MSJQCBORNZDNDU-UHFFFAOYSA-D decasodium 3-methoxy-6-[2-(6-methoxy-4,5-disulfonatooxyoxan-3-yl)oxy-5-[5-(5-methoxy-3,4-disulfonatooxyoxan-2-yl)oxy-3,4-disulfonatooxyoxan-2-yl]oxy-4-sulfonatooxyoxan-3-yl]oxy-4,5-disulfonatooxyoxane-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COC1COC(OC2COC(OC3COC(OC4COC(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C(OC4OC(C(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C([O-])=O)C3OS([O-])(=O)=O)C(OS([O-])(=O)=O)C2OS([O-])(=O)=O)C(OS([O-])(=O)=O)C1OS([O-])(=O)=O MSJQCBORNZDNDU-UHFFFAOYSA-D 0.000 description 13
229940043249 elmiron Drugs 0.000 description 13
241001465754 Metazoa Species 0.000 description 11
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
241000124008 Mammalia Species 0.000 description 6
235000014659 low sodium diet Nutrition 0.000 description 6
230000036765 blood level Effects 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
230000003562 morphometric effect Effects 0.000 description 5
238000013425 morphometry Methods 0.000 description 5
238000012453 sprague-dawley rat model Methods 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000003304 gavage Methods 0.000 description 4
230000001434 glomerular Effects 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
210000002565 arteriole Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
231100000268 induced nephrotoxicity Toxicity 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000002792 vascular Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
244000309464 bull Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
206010061989 glomerulosclerosis Diseases 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
230000000495 immunoinflammatory effect Effects 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
206010053177 Epidermolysis Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
240000000731 Fagus sylvatica Species 0.000 description 1
235000010099 Fagus sylvatica Nutrition 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
241000721701 Lynx Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
229930094280 aldehydo-D-xylose Natural products 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000306 component Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000009795 derivation Methods 0.000 description 1
229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
208000013435 necrotic lesion Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000001180 sulfating effect Effects 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Cephalosporin Compounds (AREA)

CZ20001274A 1997-10-09 1998-10-09 Lék pro prevenci nefrotoxicity nebo renální dysfunkce a farmaceutický prostredek CZ297440B6 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6294797P	1997-10-09	1997-10-09

Publications (2)

Publication Number	Publication Date
CZ20001274A3 CZ20001274A3 (cs)	2001-12-12
CZ297440B6 true CZ297440B6 (cs)	2006-12-13

Family

ID=22045901

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20001274A CZ297440B6 (cs)	1997-10-09	1998-10-09	Lék pro prevenci nefrotoxicity nebo renální dysfunkce a farmaceutický prostredek

Country Status (23)

Country	Link
US (1)	US6187745B1 (fr)
EP (1)	EP1027053B1 (fr)
JP (1)	JP2001519392A (fr)
KR (1)	KR100515196B1 (fr)
CN (1)	CN1154492C (fr)
AT (1)	ATE269098T1 (fr)
AU (1)	AU748495B2 (fr)
BR (1)	BR9813860A (fr)
CA (1)	CA2304374A1 (fr)
CZ (1)	CZ297440B6 (fr)
DE (1)	DE69824619T2 (fr)
DK (1)	DK1027053T3 (fr)
ES (1)	ES2221714T3 (fr)
HU (1)	HUP0003904A3 (fr)
IL (1)	IL135235A0 (fr)
NO (1)	NO20001828L (fr)
NZ (1)	NZ503493A (fr)
PL (1)	PL191993B1 (fr)
PT (1)	PT1027053E (fr)
RU (1)	RU2191020C2 (fr)
SK (1)	SK285332B6 (fr)
UA (1)	UA65587C2 (fr)
WO (1)	WO1999018961A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001052867A1 (fr)	2000-01-19	2001-07-26	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Utilisation de polysulfate de pentosan pour le traitement de certains troubles de la prostate
US6613083B2 (en) *	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
IL160761A0 (en) *	2001-10-19	2004-08-31	Isotechnika Inc	Novel cyclosporin analog microemulsion preconcentrates
IL164185A0 (en) *	2002-04-16	2005-12-18	Fujisawa Pharmaceutical Co	Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
ES2399277T3 (es)	2004-05-27	2013-03-27	Baxter International Inc.	Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2010020423A2 (fr)	2008-08-22	2010-02-25	Baxter Healthcare S.A.	Méthodes de traitement de troubles du saignement
JP6393453B2 (ja)	2010-01-14	2018-09-19	バクスアルタゲーエムベーハー	出血性障害を治療するための方法及び組成物
US8871741B2 (en) *	2010-01-15	2014-10-28	Icahn School Of Medicine At Mount Sinai	Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) *	2010-09-01	2012-01-25	吴洪	戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
EP2734213B1 (fr)	2011-07-19	2018-06-06	Baxalta GmbH	Activateurs de résorption comme additifs pour améliorer la formulation orale de polysaccharides sulfatés non anticoagulants
WO2013052380A2 (fr)	2011-10-05	2013-04-11	Allergan, Inc.	Composition pour améliorer la santé des ongles
EP2885642B1 (fr)	2012-08-14	2019-05-15	Baxalta GmbH	Procédés et systèmes de criblage de compositions comprenant des polysaccharides sulfatés non coagulants
KR101760510B1 (ko)	2014-12-18	2017-07-21	가톨릭대학교 산학협력단	메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (fr) *	2014-12-18	2016-06-23	가톨릭대학교 산학협력단	Composition pour atténuer la néphrotoxicité résultant de l'administration de médicament immunosuppresseur, contenant de la metformine, et composition pour la prévention ou le traitement de maladies immunitaires la contenant
WO2016199161A2 (fr) *	2015-06-12	2016-12-15	Swati Vishal Jajodia	Composition comprenant du pentosane polysulfate sodium à utiliser dans le traitement des symptômes de l'obstruction du col de la vessie et/ou d'un trouble du tractus urinaire inférieur

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3843241A1 (de) *	1988-12-22	1990-06-28	Skrezek Christian	Nephroprotektive infusionsloesung
EP0466315A3 (en)	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en)	1990-06-11	1993-04-20	Du Pont Merck Pharmaceutical Company	Treatment of organ transplantation rejection
GB9116836D0 (en) *	1991-08-05	1991-09-18	Sandoz Ltd	Organic compounds
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) *	1992-04-14	1995-01-27	Северо-Кавказский горно-металлургический институт	Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) *	1995-01-20	1997-11-04	Sigma Tau Ind Farmaceuti	Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) *	1995-02-03	1996-08-13	L T T Kenkyusho:Kk	腎不全治療剤
US5643892A (en) *	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases

1998
- 1998-09-10 UA UA2000041980A patent/UA65587C2/uk unknown
- 1998-10-01 US US09/168,974 patent/US6187745B1/en not_active Expired - Fee Related
- 1998-10-09 AT AT98952186T patent/ATE269098T1/de not_active IP Right Cessation
- 1998-10-09 EP EP98952186A patent/EP1027053B1/fr not_active Expired - Lifetime
- 1998-10-09 AU AU97943/98A patent/AU748495B2/en not_active Ceased
- 1998-10-09 PL PL339774A patent/PL191993B1/pl not_active IP Right Cessation
- 1998-10-09 RU RU2000111495/14A patent/RU2191020C2/ru not_active IP Right Cessation
- 1998-10-09 NZ NZ503493A patent/NZ503493A/en unknown
- 1998-10-09 ES ES98952186T patent/ES2221714T3/es not_active Expired - Lifetime
- 1998-10-09 JP JP2000515596A patent/JP2001519392A/ja active Pending
- 1998-10-09 DE DE69824619T patent/DE69824619T2/de not_active Expired - Fee Related
- 1998-10-09 WO PCT/US1998/021313 patent/WO1999018961A1/fr not_active Ceased
- 1998-10-09 CZ CZ20001274A patent/CZ297440B6/cs not_active IP Right Cessation
- 1998-10-09 HU HU0003904A patent/HUP0003904A3/hu unknown
- 1998-10-09 SK SK467-2000A patent/SK285332B6/sk unknown
- 1998-10-09 DK DK98952186T patent/DK1027053T3/da active
- 1998-10-09 BR BR9813860-0A patent/BR9813860A/pt not_active Application Discontinuation
- 1998-10-09 IL IL13523598A patent/IL135235A0/xx not_active IP Right Cessation
- 1998-10-09 KR KR10-2000-7003305A patent/KR100515196B1/ko not_active Expired - Fee Related
- 1998-10-09 CA CA002304374A patent/CA2304374A1/fr not_active Abandoned
- 1998-10-09 PT PT98952186T patent/PT1027053E/pt unknown
- 1998-10-09 CN CNB988100363A patent/CN1154492C/zh not_active Expired - Fee Related
2000
- 2000-04-07 NO NO20001828A patent/NO20001828L/no unknown

Also Published As

Publication number	Publication date
HK1026845A1 (en)	2000-12-29
CN1154492C (zh)	2004-06-23
UA65587C2 (en)	2004-04-15
AU9794398A (en)	1999-05-03
DE69824619D1 (de)	2004-07-22
KR100515196B1 (ko)	2005-09-16
ATE269098T1 (de)	2004-07-15
EP1027053B1 (fr)	2004-06-16
NO20001828D0 (no)	2000-04-07
AU748495B2 (en)	2002-06-06
CA2304374A1 (fr)	1999-04-22
PL339774A1 (en)	2001-01-02
NZ503493A (en)	2001-11-30
CZ20001274A3 (cs)	2001-12-12
WO1999018961A1 (fr)	1999-04-22
SK4672000A3 (en)	2001-09-11
CN1275080A (zh)	2000-11-29
EP1027053A1 (fr)	2000-08-16
PL191993B1 (pl)	2006-08-31
DK1027053T3 (da)	2004-09-06
IL135235A0 (en)	2001-05-20
ES2221714T3 (es)	2005-01-01
HUP0003904A1 (hu)	2001-08-28
HUP0003904A3 (en)	2006-06-28
SK285332B6 (sk)	2006-11-03
DE69824619T2 (de)	2005-06-23
NO20001828L (no)	2000-05-15
EP1027053A4 (fr)	2002-05-22
JP2001519392A (ja)	2001-10-23
US6187745B1 (en)	2001-02-13
RU2191020C2 (ru)	2002-10-20
KR20010030749A (ko)	2001-04-16
PT1027053E (pt)	2004-09-30
BR9813860A (pt)	2001-03-20

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic
2008-04-23	MM4A	Patent lapsed due to non-payment of fee	Effective date: 20071009

Publication	Publication Date	Title
CZ297440B6 (cs)	2006-12-13	Lék pro prevenci nefrotoxicity nebo renální dysfunkce a farmaceutický prostredek
JP4149905B2 (ja)	2008-09-17	サイクロスポリンａおよび４０−ｏ−（２−ヒドロキシエチル）−ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物
MXPA04010170A (es)	2005-02-03	Medicamento para prevenir y/o tratar el rechazo cronico.
EP1496929A1 (fr)	2005-01-19	Utilisation d'un antagoniste du recepteur c5a dans le traitement de la fibrose
Bennett	1996	Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs
Dias et al.	1998	Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits
Pally et al.	2001	Tolerability profile of sodium mycophenolate (ERL080) and mycophenolate mofetil with and without cyclosporine (Neoral) in the rat
Tejani et al.	1988	NEPHROTOXICITY OF CYCLOSPORINE A AND CYCLOSPORINE G IN A RAT MODEL1
ES2261447T3 (es)	2006-11-16	Antagonistas no peptidicos del receptor ccr1 en combinacion con ciclosporina a para el tratamiento del rechazo de los transplantes de corazon.
MXPA00003194A (en)	2002-02-26	Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
Nakamura et al.	2018	Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates
HK1026845B (en)	2004-12-10	Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus
Li et al.	2004	Synergistic effect of triptolide and tacrolimus on rat cardiac allotransplantation
AU2001261248A1 (en)	2001-11-20	Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
AU2001278073A1 (en)	2002-05-09	Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
WO2006033024A2 (fr)	2006-03-30	Procede de maximisation de l'efficacite et de prevision et minimisation de la toxicite de composes inhibiteurs de calcineurine
EP1641482A1 (fr)	2006-04-05	Methode de traitement de lesions systemiques consecutives a des brulures
CN1236617A (zh)	1999-12-01	一种免疫抑制药物
Sharma et al.	2015	A Review on Pharmacology of Tacrolimus In Renal Transplant Patients
AU2004241673A1 (en)	2004-12-02	Method of treatment of systemic injury secondary to burns
HK1148665A1 (en)	2011-09-16	Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy
HK1148665B (en)	2013-08-02	Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy